Disruption of RB signaling as an early event is consistent with both the necessity of passing the G1/S cell cycle checkpoint to allow the development of a tumor and the observation of RB pathway mutations in the majority of low- and high-grade gliomas [43]. This evidence concerns the gene RB1 and central nervous system cancer.